top of page

Occam Places Gurpreet Ratra as CBO at Skyline

Skyline Therapeutics, an F-Prime/Eight Roads investment, is a cell & gene therapy company developing novel genetic medicines across multiple therapeutic areas for global markets. The company has extensive R&D and manufacturing operations in Shanghai and affiliate offices in the U.S.

In August 2020, Occam recruited Gurpreet Ratra, PhD as the company’s CBO. Prior to joining Skyline, Gurpreet served as Head of Business Development at Spark Therapeutics.

bottom of page